University of Shizuoka   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Shizuoka City Japan (1987)

Organization Overview

First Clinical Trial
2004
NCT00307996
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Masahiro Morikawa | Shizuoka Cancer Cener, Division of Gastrointestinal Oncology | Shizuoka Cancer Center | Shizuoka Cancer Center Hospital | Shizuoka Cancer Center, Japan | Shizuoka General Hospital

Active Ingredients

Drugs in Phase 4 Trials (1)

ubiquinone (1 trial)

Drugs in Phase 3 Trials (2)

epinephrine (levophed) (1 trial)

tea (1 trial)

Drugs in Phase 2 Trials (6)

gimeracil (3 trials)

leucovorin (1 trial)

oteracil (3 trials)

oxaliplatin (eloxatin) (1 trial)

s-1 (3 trials)

tegafur (3 trials)

Drugs in Phase 1 Trials (3)

capecitabine (xeloda) (1 trial)

cediranib (1 trial)

cisplatin (platinol) (1 trial)

Drugs in Other Trials (3)

epicatechin (5 trials)

l-epigallocatechin (1 trial)

theanine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 2)

Communicable Diseases (Phase 3)

Infections (Phase 3)

Influenza, Human (Phase 3)

Kidney Failure, Chronic (Phase 4)

Pancreatic Neoplasms (Phase 2)

Stomach Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial APIs: 15